Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Apple

Accenture Plc

Automatic Data Processing

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

American Water Works

Booz Allen Hamilton Hld

SPDR Bloomberg 1-3 Month T-Bill ETF

Booking Hlds

Blackrock Inc

Broadridge Financial

CME Group

Canadian National Railway Company

Canadian Pacific Kansas City Limited

Camden Property

Salesforce

Carlisle Companies

Deere & Company

Ecolab

Retirement strategies are not one-size-fits-all due to individual variables like nest egg size, lifestyle costs, and goals. Conventional retirement plans like real estate investing and the 4% rule have pros and cons, influencing personal retirement strategies. My retirement plan prioritizes passive income generation, dividend growth, and active portfolio management to avoid forced asset sales and ensure financial freedom.

If I Had To Retire Today, Here's How I'd Do It

Cardinal Health

Fiserv Inc

Globe Life Inc

JPMorgan Chase & Co

Merck

ONEOK

Omnicom Group

Amplify Blackswan Growth & Treasury Core ETF

Innovator Equity Defined Protection ETF - 2 Yr to July 2025

Vulcan Materials

Exxon Mobil

You don't get upset for having homeowner's insurance but your house doesn't burn down. The same principle should apply to investors who insure their stock portfolios against a crash.

‘Crash proof' your portfolio with these 10 stocks and 3 ETFs

Alnylam Pharmaceuticals

Exelixis

Gilead Sciences

Harmony Biosciences Holdings

Incyte

Bio-Techne

Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive.

7 Cheap Biotech Stocks With Major Upside Potential

Phillips 66

With technology-driven growth stocks propelling the S&P 500 to new heights, dividend stocks have often found themselves playing catch-up. Yet, even in this market environment, some dividend-paying companies have managed not only to keep pace, but also beat the index by a significant margin.

3 Dividend Stocks Crushing the S&P 500 With 30%+ Annual Total Returns

Amgen shares have outperformed IBB by over 40% in the past year, driven higher by a major surge post-earnings in May. With a current price-to-earnings multiple in the mid-teens, I assert that solid and consistent EPS growth ahead warrants a higher valuation. AMGN's chart is also impressive, with a long-term uptrend in place.

Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum

Abbott Labs

Eli Lilly

The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for investors.

The 3 Best Healthcare Stocks to Buy in July 2024

Viking Therapeutics

Vertex Pharmaceuticals

Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.

Forget Eli Lilly: 3 Biotech Stocks to Buy Instead

Amgen has maintained an impressive dividend streak over the past decade. The company's business should allow it to maintain this momentum for a while.

1 Dividend Growth Stock to Buy and Hold for 10 Years

ConocoPhillips

AXA Equitable Holdings Inc

International Paper

PepsiCo

24/7 Wall St. Insights Jefferies is one of Wall Street's fastest-growing firms.

Jefferies Red-Hot Summer Top Stock Picks Include 5 Blue Chip Dividend Giants

Amgen has been one of the best performing stocks since its IPO in 1983. Over the prior 12 months, the biotech's shares have continued this rich tradition.

Can Amgen Stock Keep Trouncing the S&P 500?

Bristol-Myers

Ionis Pharma

SPDR S&P Biotech ETF

Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.

M&A Is Back. 4 Stocks That Could Be Targets.

bluebird bio

Neurocrine Biosciences

Novartis

Ultragenyx Pharmaceutical

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients with B-precursor acute lymphoblastic leukemia. Ten days earlier, the company released promising results from a Phase 3 clinical trial evaluating Uplizna's efficacy in treating Immunoglobulin G4-related disease.

Amgen: You Haven't Seen Anything Yet

Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.

Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

Travelers

Dow Jones stocks to watch in the stock market this week.

Top Dow Jones Stocks To Buy Today? 2 To Know

BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy Alone First and Only  Bispecific T-cell Engager  (BiTE ® ) Therapy for Consolidation Treatment Regardless of Measurable Residual Disease (MRD) Status THOUSAND OAKS, Calif. , June 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

Novo Nordisk

Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand.

3 Stocks to Buy as Ozempic Surges in Popularity

Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA ® and Progress in Addressing Sjögren's Disease THOUSAND OAKS, Calif. , June 12, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna.

AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024

Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 9:20 AM ET Company Participants James E. Bradner – EVP of Research and Development & Chief Scientific Officer Peter H.

Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference Transcript

News for Amgen Stock (AMGN)